These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 31183356)

  • 21. Performance of different methods for detecting T790M mutation in the plasma of patients with advanced NSCLC after developing resistance to first-generation EGFR-TKIs in a real-world clinical setting.
    Hou T; Zeng J; Xu H; Su S; Ye J; Li Y
    Mol Clin Oncol; 2022 Apr; 16(4):88. PubMed ID: 35251639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The emergence of various genetic alterations mediated the Osimertinib resistance of a patient harboring heterozygous germline EGFR T790M: a case report.
    Liu B; Qin J; Yin Y; Zhai L; Liu G; Lizaso A; Shi D
    Ann Transl Med; 2021 Jan; 9(1):80. PubMed ID: 33553373
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Pisapia P; Rocco D; Pepe F; De Luca C; Battiloro C; Smeraglio R; Cieri M; Bellevicine C; Troncone G; Malapelle U
    Transl Cancer Res; 2019 Jan; 8(Suppl 1):S64-S69. PubMed ID: 35117065
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.
    Liao BC; Lin CC; Lee JH; Yang JC
    Lung Cancer; 2017 Aug; 110():7-13. PubMed ID: 28676222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.
    Lee CK; Kim S; Lee JS; Lee JE; Kim SM; Yang IS; Kim HR; Lee JH; Kim S; Cho BC
    Lung Cancer; 2017 Nov; 113():106-114. PubMed ID: 29110836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of genomic alternations in epidermal growth factor receptor (EGFR)-T790M-mutated non-small cell lung cancer (NSCLC) patients with acquired resistance to osimertinib therapy.
    Hsu PC; Chang JW; Chiu LC; Yang CT; Kuo SC; Fang YF; Wu CE
    Clin Transl Oncol; 2024 Sep; ():. PubMed ID: 39317868
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (
    Xu Z; Hao X; Wang Q; Wang J; Yang K; Wang S; Teng F; Li J; Xing P
    Cancer Manag Res; 2022; 14():863-873. PubMed ID: 35256860
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation.
    Watanabe K; Saito R; Miyauchi E; Nagashima H; Nakamura A; Sugawara S; Tanaka N; Terasaki H; Fukuhara T; Maemondo M
    Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
    Tan CS; Cho BC; Soo RA
    Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations.
    Masuzawa K; Yasuda H; Hamamoto J; Nukaga S; Hirano T; Kawada I; Naoki K; Soejima K; Betsuyaku T
    Oncotarget; 2017 Dec; 8(62):105479-105491. PubMed ID: 29285266
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Osimertinib - effective treatment of NSCLC with activating
    Skrzypski M; Szymanowska-Narloch A; Dziadziuszko R
    Contemp Oncol (Pozn); 2017; 21(3):254-258. PubMed ID: 29180936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real-world clinical example.
    Wei B; Zhao C; Li J; Zhao J; Ren P; Yang K; Yan C; Sun R; Ma J; Guo Y
    Mol Oncol; 2019 May; 13(5):1226-1234. PubMed ID: 30927306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ; Drilon A; Santini FC
    Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acquisition of T790M resistance mutation in a patient with advanced adenocarcinoma harbouring uncommon
    Hakozaki T; Yomota M
    Onco Targets Ther; 2019; 12():745-748. PubMed ID: 30774361
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rechallenge with erlotinib in osimertinib-resistant lung adenocarcinoma mediated by driver gene loss: a case report.
    Liu L; Lizaso A; Mao X; Yang N; Zhang Y
    Transl Lung Cancer Res; 2020 Feb; 9(1):144-147. PubMed ID: 32206561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Standard dose osimertinib for erlotinib refractory T790M-negative
    Arulananda S; Do H; Rivalland G; Loh Z; Musafer A; Lau E; Mitchell P; Dobrovic A; John T
    J Thorac Dis; 2019 May; 11(5):1756-1764. PubMed ID: 31285867
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Osimertinib.
    Malapelle U; Ricciuti B; Baglivo S; Pepe F; Pisapia P; Anastasi P; Tazza M; Sidoni A; Liberati AM; Bellezza G; Chiari R; Metro G
    Recent Results Cancer Res; 2018; 211():257-276. PubMed ID: 30069773
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Zheng Q; Huang Y; Zhao H; Yang Y; Hong S; Hou X; Zhao Y; Ma Y; Zhou T; Zhang Y; Fang W; Zhang L
    Transl Lung Cancer Res; 2020 Jun; 9(3):471-483. PubMed ID: 32676311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation.
    Joshi A; Butle A; Hait S; Mishra R; Trivedi V; Thorat R; Choughule A; Noronha V; Prabhash K; Dutt A
    Transl Oncol; 2022 Aug; 22():101461. PubMed ID: 35653897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advanced lung adenocarcinoma (LUAD) patient with EGFR mutations benefited from multiline combination targeted therapies after osimertinib (AZD9291) resistance: a case report.
    Chen J; Zhao X; Wang J; Liu F; Zhang L; Chen Y; Chu Q
    Transl Cancer Res; 2022 Sep; 11(9):3343-3348. PubMed ID: 36237272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.